世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000033636

抗ウイルス薬市場レポート2022-2032

Visiongain

Antiviral Drugs Market Report 2022-2032

発刊日 2022/11/17

言語英語

体裁PDF/285ページ

ライセンス/価格285ページ

0000033636

Single - 1 Year License
(Team License - Up to 6 Users) - 1 Year License
Site
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数6人)をご検討ください。
※詳しくはお問い合わせください。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

薬剤クラス別予測 (DNA ポリメラーゼ阻害剤、逆転写酵素阻害剤、プロテアーゼ阻害剤、ノイラミニダーゼ阻害剤、その他)、用途別 (HIV/AIDS、インフルエンザ、肝炎、ヘルペス、その他)、エンドユーザー別 (病院、診療所、その他)、年齢別 (成人、小児、高齢者)、種類別 (ブランド医薬品、ジェネリック医薬品) 、および 地域&主要国市場別分析、 プラス主要企業の分析、およびCOVID-19 の影響と回復パターンの分析

新しい収益源を求めて、業界とその根底にあるダイナミクスについて理解を深めたいと考えている大手企業にとって、このレポートは非常に貴重な資料です。さまざまな業種に進出したり、新たな地域で既存の事業を拡大したい企業を支援します。

市場の成長を後押しするブロックバスター医薬品の導入

抗ウイルス薬は、多くの大手製薬会社によって活発に研究開発が行われています。Gilead Science の Biktarvy や GlaxoSmithKline の Triumeq のようなブロックバスター医薬品の出現以来、抗レトロウイルス療法が劇的に進化しました。このような大ヒット薬の消費の増加と生産者による流通の増加によって、2022年から2032年までに抗ウイルス市場の売上は増加すると予想されます。

COVID-19 のパンデミックによって、抗ウイルス薬の需要が高まっています。 COVID-19の症例が急増し、医療施設は主にCOVID-19患者の治療に力を注いだことから市場が拡大しました。 さらに、多くの製薬会社は、患者により良い治療成績とより効果的な治療法を提供するために、新薬の開発に力を注いでいます。これらの企業は、この期間を通じて製品の需要を満たすために協力しました。

レポート詳細

目次

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Antiviral Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Growing Viral Diseases Burden
3.2.1.2 Introduction of Blockbuster Therapeutics to Boost Market Growth
3.2.2 Market Restraining Factors
3.2.2.1 High Stringency Related to Product Approvals Likely to Hamper Market Growth
3.2.2.2 High Cost of Drug Development
3.2.3 Market Opportunities
3.2.3.1 Robust Investment in R&D Activities by Numerous Pharmaceutical Organizations
3.2.3.2 Growing Viral Disease Creating Demand for Antiviral Drugs
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political Factors Impacting Antiviral Drug Market
3.5.2 Economic Factors Impacting Antiviral Drug Market
3.5.3 Social Factors Impacting Antiviral Drug Market
3.5.4 Technological Factors Impacting Antiviral Drug Market

4 Antiviral Drugs Market Analysis by Drug Class
4.1 Key Findings
4.2 Drug Class Segment: Market Attractiveness Index
4.3 Antiviral Drugs Market Share by Drug Class, 2022 & 2032
4.4 DNA Polymerase Inhibitors
4.4.1 Market Size by Region, 2022-2032 (US$ bn)
4.4.2 Market Share by Region, 2022 & 2032 (%)
4.5 Reverse Transcriptase Inhibitors
4.5.1 Market Size by Region, 2022-2032 (US$ bn)
4.5.2 Market Share by Region, 2022 & 2032 (%)
4.6 Protease Inhibitors
4.6.1 Market Size by Region, 2022-2032 (US$ bn)
4.6.2 Market Share by Region, 2022 & 2032 (%)
4.7 Neuraminidase Inhibitors
4.7.1 Market Size by Region, 2022-2032 (US$ bn)
4.7.2 Market Share by Region, 2022 & 2032 (%)
4.8 Others
4.8.1 Market Size by Region, 2022-2032 (US$ bn)
4.8.2 Market Share by Region, 2022 & 2032 (%)

5 Antiviral Drugs Market Analysis by Application
5.1 Key Findings
5.2 Application Segment: Market Attractiveness Index
5.3 Antiviral Drugs Market Share by Application, 2022 & 2032
5.4 Hepatitis
5.4.1 Market Size by Region, 2022-2032 (US$ bn)
5.4.2 Market Share by Region, 2022 & 2032 (%)
5.5 HIV
5.5.1 Market Size by Region, 2022-2032 (US$ bn)
5.5.2 Market Share by Region, 2022 & 2032 (%)
5.6 Influenza
5.6.1 Market Size by Region, 2022-2032 (US$ bn)
5.6.2 Market Share by Region, 2022 & 2032 (%)
5.7 Herpes
5.7.1 Market Size by Region, 2022-2032 (US$ bn)
5.7.2 Market Share by Region, 2022 & 2032 (%)
5.8 Others
5.8.1 Market Size by Region, 2022-2032 (US$ bn)
5.8.2 Market Share by Region, 2022 & 2032 (%)

6 Antiviral Drugs Market Analysis by End User
6.1 Key Findings
6.2 End-users Segment: Market Attractiveness Index
6.3 Antiviral Drugs Market Share by End-users, 2022 & 2032
6.4 Hospitals
6.4.1 Market Size by Region, 2022-2032 (US$ bn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 Clinics
6.5.1 Market Size by Region, 2022-2032 (US$ bn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
6.6 Others
6.6.1 Market Size by Region, 2022-2032 (US$ bn)
6.6.2 Market Share by Region, 2022 & 2032 (%)

7 Antiviral Drugs Market Analysis by Age Group
7.1 Key Findings
7.2 Age Group Segment: Market Attractiveness Index
7.3 Antiviral Drugs Market Share by Age Group, 2022 & 2032
7.4 Adults
7.4.1 Market Size by Region, 2022-2032 (US$ bn)
7.4.2 Market Share by Region, 2022 & 2032 (%)
7.5 Geriatrics
7.5.1 Market Size by Region, 2022-2032 (US$ bn)
7.5.2 Market Share by Region, 2022 & 2032 (%)
7.6 Pediatrics
7.6.1 Market Size by Region, 2022-2032 (US$ bn)
7.6.2 Market Share by Region, 2022 & 2032 (%)

8 Antiviral Drugs Market Analysis by Type
8.1 Key Findings
8.2 Type Segment: Market Attractiveness Index
8.3 Antiviral Drugs Market Share by Type, 2022 & 2032
8.4 Branded Drugs
8.4.1 Market Size by Region, 2022-2032 (US$ bn)
8.4.2 Market Share by Region, 2022 & 2032 (%)
8.5 Generic Drugs
8.5.1 Market Size by Region, 2022-2032 (US$ bn)
8.5.2 Market Share by Region, 2022 & 2032 (%)

9 Antiviral Drugs Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast
9.3 COVID-19 Impact Analysis

10 North America Antiviral Drugs Market Analysis
10.1 Key Findings
10.2 North America Antiviral Drugs Market Attractiveness Index
10.3 North America Antiviral Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
10.4 North America Antiviral Drugs Market Size Estimation and Forecast by Country
10.5 North America Antiviral Drugs Market Size Estimation and Forecast by Drug Class
10.6 North America Antiviral Drugs Market Size Estimation and Forecast by Application
10.7 North America Antiviral Drugs Market Size Estimation and Forecast by End-users
10.8 North America Antiviral Drugs Market Size Estimation and Forecast by Age Group
10.9 North America Antiviral Drugs Market Size Estimation and Forecast by Type
10.10 U.S. Antiviral Drugs Market Analysis
10.11 Canada Antiviral Drugs Market Analysis

11 Europe Antiviral Drugs Market Analysis
11.1 Key Findings
11.2 Europe Antiviral Drugs Market Attractiveness Index
11.3 Europe Antiviral Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
11.4 Europe Antiviral Drugs Market Size Estimation and Forecast by Country
11.5 Europe Antiviral Drugs Market Size Estimation and Forecast by Drug Class
11.6 Europe Antiviral Drugs Market Size Estimation and Forecast by Application
11.7 Europe Antiviral Drugs Market Size Estimation and Forecast by End-users
11.8 Europe Antiviral Drugs Market Size Estimation and Forecast by Age Group
11.9 Europe Antiviral Drugs Market Size Estimation and Forecast by Type
11.10 Germany Antiviral Drugs Market Analysis
11.11 U.K. Antiviral Drugs Market Analysis
11.12 France Antiviral Drugs Market Analysis
11.13 Italy Antiviral Drugs Market Analysis
11.14 Spain Antiviral Drugs Market Analysis
11.15 Russia Antiviral Drugs Market Analysis
11.16 Rest of Europe Antiviral Drugs Market Analysis

12 Asia Pacific Antiviral Drugs Market Analysis
12.1 Key Findings
12.2 Asia Pacific Antiviral Drugs Market Attractiveness Index
12.3 Asia Pacific Antiviral Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
12.4 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by Country
12.5 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by Drug Class
12.6 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by Application
12.7 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by End-users
12.8 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by Age Group
12.9 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by Type
12.10 China Antiviral Drugs Market Analysis
12.11 Japan Antiviral Drugs Market Analysis
12.12 India Antiviral Drugs Market Analysis
12.13 Australia Antiviral Drugs Market Analysis
12.14 South Korea Antiviral Drugs Market Analysis
12.15 Rest of Asia Pacific Antiviral Drugs Market Analysis

13 Latin America Antiviral Drugs Market Analysis
13.1 Key Findings
13.2 Latin America Antiviral Drugs Market Attractiveness Index
13.3 Latin America Antiviral Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
13.4 Latin America Antiviral Drugs Market Size Estimation and Forecast by Country
13.5 Latin America Antiviral Drugs Market Size Estimation and Forecast by Drug Class
13.6 Latin America Antiviral Drugs Market Size Estimation and Forecast by Application
13.7 Latin America Antiviral Drugs Market Size Estimation and Forecast by End-users
13.8 Latin America Antiviral Drugs Market Size Estimation and Forecast by Age Group
13.9 Latin America Antiviral Drugs Market Size Estimation and Forecast by Type
13.10 Brazil Antiviral Drugs Market Analysis
13.11 Mexico Antiviral Drugs Market Analysis
13.12 Rest of Latin America Antiviral Drugs Market Analysis

14 Middle East & Africa Antiviral Drugs Market Analysis
14.1 Key Findings
14.2 Middle East & Africa Antiviral Drugs Market Attractiveness Index
14.3 Middle East & Africa Antiviral Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
14.4 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by Country
14.5 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by Drug Class
14.6 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by Application
14.7 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by End-users
14.8 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by Age Group
14.9 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by Type
14.10 GCC Antiviral Drugs Market Analysis
14.11 South Africa Antiviral Drugs Market Analysis
14.12 Rest of Middle East & Africa Antiviral Drugs Market Analysis

15 Company Profiles
15.1 Company Share Analysis
15.2 Key Business Strategy Analysis
15.3 Johnson & Johnson Services, Inc.
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2017-2021
15.3.3.2 Regional Revenue/Market Shares, 2021
15.3.3.3 Segmental Revenue/Market Shares, 2021
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 Merck KGaA
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2017-2021
15.4.3.2 Regional Revenue/Market Shares, 2021
15.4.3.3 Segmental Revenue/Market Shares, 2021
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 GlaxoSmithKline plc.
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2017-2021
15.5.3.2 Regional Revenue/Market Shares, 2021
15.5.3.3 Segmental Revenue/Market Shares, 2021
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.6 Novartis AG
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2017-2021
15.6.3.2 Regional Revenue/Market Shares, 2021
15.6.3.3 Segmental Revenue/Market Shares, 2021
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 F. Hoffmann-La Roche Ltd
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2017-2021
15.7.3.2 Regional Revenue/Market Shares, 2021
15.7.3.3 Segmental Revenue/Market Shares, 2021
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 AstraZeneca
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2017-2021
15.8.3.2 Regional Revenue Shares, 2021
15.8.4 Product Benchmarking
15.8.5 Strategic Outlook
15.9 Bristol-Myers Squibb Company
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2017-2021
15.9.3.2 Regional Revenue Shares, 2021
15.9.4 Product Benchmarking
15.9.5 Strategic Outlook
15.10 AbbVie Inc.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2017-2021
15.10.3.2 Product Revenue Shares, 2021
15.10.3.3 Regional Revenue Shares, 2021
15.10.4 Product Benchmarking
15.10.5 Strategic Outlook
15.11 Gilead Sciences, Inc.
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2017-2021
15.11.3.2 Product Revenue Shares, 2021
15.11.3.3 Regional Revenue Shares, 2021
15.11.4 Product Benchmarking
15.11.5 Strategic Outlook
15.12 Boehringer Ingelheim International GmbH
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 Net Revenue, 2017-2021
15.12.3.2 Product Revenue Shares, 2021
15.12.3.3 Regional Revenue Shares, 2021
15.12.4 Product Benchmarking
15.12.5 Strategic Outlook
15.13 Cipla Inc.
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Product Revenue Shares, 2021
15.13.4 Product Benchmarking
15.13.5 Strategic Outlook
15.14 Abbott
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Financial Analysis
15.14.3.1 Net Revenue, 2017-2021
15.14.3.2 Product Revenue Shares, 2021
15.14.3.3 Regional Revenue Shares, 2021
15.14.4 Product Benchmarking
15.15 Viatris (Mylan N. V.)
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 Net Revenue, 2017-2021
15.15.3.2 Regional Revenue Shares, 2021
15.15.4 Product Benchmarking
15.15.5 Strategic Outlook
15.16 Sun Pharmaceutical Industries Ltd.
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Financial Analysis
15.16.3.1 Net Revenue, 2017-2021
15.16.3.2 Regional Revenue Shares, 2021
15.16.4 Product Benchmarking
15.17 Aurobindo Pharma
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Financial Analysis
15.17.3.1 Net Revenue, 2017-2021
15.17.4 Product Benchmarking
15.18 Dr. Reddy’s Laboratories Ltd.
15.18.1 Company Snapshot
15.18.2 Company Overview
15.18.3 Financial Analysis
15.18.3.1 Net Revenue, 2017-2021
15.18.3.2 Product Revenue Shares, 2021
15.18.4 Product Benchmarking
15.18.5 Strategic Outlook

16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players

List of Tables
Table 1 Antiviral Drugs Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Estimated Number of People Living with HIV, 2020−2021
Table 3 HIV-related Deaths, 2020−2021
Table 4 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “V” Shaped Recovery Scenario
Table 5 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “U” Shaped Recovery Scenario
Table 6 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “W” Shaped Recovery Scenario
Table 7 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “L” Shaped Recovery Scenario
Table 8 Commonly used DNA Polymerase Inhibitors
Table 9 DNA Polymerase Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 10 Commonly used Reverse Transcriptase Inhibitors
Table 11 Reverse Transcriptase Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 12 Protease Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 13 Commonly used Neuraminidase Inhibitor’s
Table 14 Neuraminidase Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 15 Other Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 16 Hepatitis Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 17 HIV Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 18 Influenza Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 19 Herpes Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 20 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 21 Hospitals Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 22 Clinics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 23 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 24 Adult Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 25 Geriatrics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 26 Pediatrics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 27 Branded Drugs Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 28 Generic Drugs Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 29 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%))
Table 30 North America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 31 North America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 32 North America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 33 North America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 34 North America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 35 North America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 36 U.S. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 37 Canada Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 38 Europe Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 39 Europe Antiviral Drugs Market Forecast by drug class, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 40 Europe Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 41 Europe Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 42 Europe Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 43 Europe Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 44 Germany Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 45 U.K. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 46 France Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 47 Italy Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 48 Spain Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 49 Russia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 50 Rest of Europe Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 51 Asia Pacific Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 52 Asia Pacific Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 53 Asia Pacific Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 54 Asia Pacific Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 55 Asia Pacific Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 56 Asia Pacific Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 57 China Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 58 Japan Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 59 India Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 60 Australia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 61 South Korea Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 62 Rest of Asia Pacific Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 63 Latin America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 64 Latin America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 65 Latin America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 66 Latin America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 67 Latin America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 68 Latin America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 69 Brazil Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 70 Mexico Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 71 Rest of Latin America Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 72 Middle East & Africa Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 73 Middle East & Africa Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 74 Middle East & Africa Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 75 Middle East & Africa Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 76 Middle East & Africa Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 77 Middle East & Africa Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 78 GCC Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 79 South Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 80 Rest of Middle East & Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 81 Antiviral Drugs Market Company Ranking for the Year 2021
F. Hoffmann-La Roche Ltd
Table 82 Johnson & Johnson Services, Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Johnson & Johnson Services Inc. : Product Benchmarking
Table 84 Johnson & Johnson Services inc. : Strategic Outlook
Table 85 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Merck KGaA : Product Benchmarking
Table 87 Merck KGaA : Strategic Outlook
Table 88 GlaxoSmithKline plc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 GlaxoSmithKline plc. : Product Benchmarking
Table 90 GlaxoSmithKline plc. : Strategic Outlook
Table 91 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 Novartis AG: Product Benchmarking
Table 93 Novartis AG: Strategic Outlook
Table 94 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 96 F. Hoffmann-La Roche Ltd : Strategic Outlook
Table 97 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 AstraZeneca: Product Benchmarking
Table 99 AstraZeneca : Strategic Outlook
Table 100 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Bristol-Myers Squibb Company: Product Benchmarking
Table 102 Bristol-Myers Squibb Company: Strategic Outlook
Table 103 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 AbbVie Inc.: Product Benchmarking
Table 105 AbbVie Inc.: Strategic Outlook
Table 106 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Gilead Sciences, Inc. Product Benchmarking
Table 108 Gilead Sciences Inc. Strategic Outlook
Table 109 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Boehringer Ingelheim International GmbH: Product Benchmarking
Table 111 Boehringer Ingelheim International GmbH; Strategic Outlook
Table 112 Cipla Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Cipla Inc.: Product Benchmarking
Table 114 Cipla Inc.: Strategic Outlook
Table 115 Abbott: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Abbott: Product Benchmarking
Table 117 Viatris: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Viatris: Product Benchmarking
Table 119 Viatris: Strategic Outlook
Table 120 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Sun Pharmaceutical Industries Ltd. : Product Benchmarking
Table 122 Aurobindo Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Aurobindo Pharma: Product Benchmarking
Table 124 Dr. Reddy’s Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 Dr. Reddy’s Laboratories ltd. : Product Benchmarking
Table 126 Dr. Reddy’s Laboratories Ltd. : Strategic Outlook
?

List of Figures
Figure 1 Antiviral Drugs Market Segmentation
Figure 2 Antiviral Drugs Market Forecast by Region: Market Attractiveness Index
Figure 3 Antiviral Drugs Market by Drug Class: Market Attractiveness Index
Figure 4 Antiviral Drugs Market by Application: Market Attractiveness Index
Figure 5 Antiviral Drugs Market by End-users: Market Attractiveness Index
Figure 6 Antiviral Drugs Market by Age Group: Market Attractiveness Index
Figure 7 Antiviral Drugs Market by Type: Market Attractiveness Index
Figure 8 Antiviral Drugs Market: Market Dynamics
Figure 9 COVID Impact Analysis: Antiviral Drugs Market Recovery Scenarios
Figure 10 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 11 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 12 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 13 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 14 Antiviral Drugs Market: Porter’s Five Forces Analysis
Figure 15 Antiviral Drugs Market: PEST Analysis
Figure 16 Antiviral Drugs Market Forecast by Drug Class Segment: Market Attractiveness Index
Figure 17 Antiviral Drugs Market Share Forecast by Drug Class, 2022, 2032 (%)
Figure 18 DNA Polymerase Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 19 DNA Polymerase Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 20 Reverse Transcriptase Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 21 Reverse Transcriptase Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 22 Protease Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 23 Protease Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 24 Neuraminidase Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 25 Neuraminidase Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 26 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 27 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 28 Antiviral Drugs Market Forecast by Application Segment: Market Attractiveness Index
Figure 29 Antiviral Drugs Market Share Forecast by Application, 2022, 2032 (%)
Figure 30 Hepatitis Market Forecast by Region, 2022-2032 (US$ billion)
Figure 31 Hepatitis Market Share Forecast by Region, 2022 & 2032 (%)
Figure 32 HIV Market Forecast by Region, 2022-2032 (US$ billion)
Figure 33 HIV Market Share Forecast by Region, 2022 & 2032 (%)
Figure 34 Influenza Market Forecast by Region, 2022-2032 (US$ billion)
Figure 35 Influenza Market Share Forecast by Region, 2022 & 2032 (%)
Figure 36 Herpes Market Forecast by Region, 2022-2032 (US$ billion)
Figure 37 Herpes Market Share Forecast by Region, 2022 & 2032 (%)
Figure 38 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 39 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 40 Antiviral Drugs Market Forecast by End-users Segment: Market Attractiveness Index
Figure 41 Antiviral Drugs Market Share Forecast by End-users, 2022, 2032 (%)
Figure 42 Hospitals Market Forecast by Region, 2022-2032 (US$ billion)
Figure 43 Hospitals Market Share Forecast by Region, 2022 & 2032 (%)
Figure 44 Clinics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 45 Clinics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 46 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 47 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 48 Antiviral Drugs Market Forecast by Age Group Segment: Market Attractiveness Index
Figure 49 Antiviral Drugs Market Share Forecast by Age Group, 2022, 2032 (%)
Figure 50 Adult Market Forecast by Region, 2022-2032 (US$ billion)
Figure 51 Adult Market Share Forecast by Region, 2022 & 2032 (%)
Figure 52 Geriatrics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 53 Geriatrics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 54 Pediatrics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 55 Pediatrics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 56 Antiviral Drugs Market Forecast by Type Segment: Market Attractiveness Index
Figure 57 Antiviral Drugs Market Share Forecast by Type, 2022, 2032 (%)
Figure 58 Branded Drugs Market Forecast by Region, 2022-2032 (US$ billion)
Figure 59 Branded Drugs Market Share Forecast by Region, 2022 & 2032 (%)
Figure 60 Generic Drugs Market Forecast by Region, 2022-2032 (US$ billion)
Figure 61 Generic Drugs Market Share Forecast by Region, 2022 & 2032 (%)
Figure 62 Antiviral Drugs Market Forecast by Region 2022 v.s. 2032 (Revenue, CAGR %)
Figure 63 Antiviral Drugs Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 64 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%))
Figure 65 North America Antiviral Drugs Market Attractiveness Index
Figure 66 North America Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 67 North America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 68 North America Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 69 North America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 70 North America Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 71 North America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 72 North America Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 73 North America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 74 North America Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 75 North America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 76 North America Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 77 North America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 78 North America Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 79 U.S. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 80 Canada Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 81 Europe Antiviral Drugs Market Attractiveness Index
Figure 82 Europe Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 83 Europe Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 84 Europe Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 85 Europe Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 86 Europe Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 87 Europe Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 88 Europe Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 89 Europe Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 90 Europe Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 91 Europe Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 92 Europe Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 93 Europe Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 94 Europe Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 95 Germany Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 96 U.K. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 97 France Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 98 Italy Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 99 Spain Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 100 Russia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 101 Rest of Europe Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 102 Asia Pacific Antiviral Drugs Market Attractiveness Index
Figure 103 Asia Pacific Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 104 Asia Pacific Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 105 Asia Pacific Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 106 Asia Pacific Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 107 Asia Pacific Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 108 Asia Pacific Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 109 Asia Pacific Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 110 Asia Pacific Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 111 Asia Pacific Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 112 Asia Pacific Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 113 Asia Pacific Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 114 Asia Pacific Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 115 Asia Pacific Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 116 China Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 117 Japan Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 118 India Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 119 Australia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 120 South Korea Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 121 Rest of Asia Pacific Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 122 Latin America Antiviral Drugs Market Attractiveness Index
Figure 123 Latin America Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 124 Latin America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 125 Latin America Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 126 Latin America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 127 Latin America Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 128 Latin America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 129 Latin America Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 130 Latin America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 131 Latin America Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 132 Latin America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 133 Latin America Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 134 Latin America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 135 Latin America Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 136 Brazil Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 137 Mexico Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 138 Rest of Latin America Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 139 Middle East & Africa Antiviral Drugs Market Attractiveness Index
Figure 140 Middle East & Africa Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 141 Middle East & Africa Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 142 Middle East & Africa Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 143 Middle East & Africa Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 144 Middle East & Africa Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 145 Middle East & Africa Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 146 Middle East & Africa Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 147 Middle East & Africa Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 148 Middle East & Africa Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 149 Middle East & Africa Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 150 Middle East & Africa Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 151 Middle East & Africa Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 152 Middle East & Africa Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 153 GCC Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 154 South Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 155 Rest of Middle East & Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 157 Johnson & Johnson Services Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 158 Johnson & Johnson Services Inc. : Regional Revenue Shares, 2021
Figure 159 Johnson & Johnson Services Inc. : Segmental Revenue Shares, 2021
Figure 160 Merck KGaA : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 161 Merck KGaA : Regional Revenue Shares, 2021
Figure 162 Merck KGaA : Segmental Revenue Shares, 2021
Figure 163 GlaxoSmithKline plc. : Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 164 GlaxoSmithKline plc. : Regional Revenue Shares, 2021
Figure 165 GlaxoSmithKline plc. : Segmental Revenue Shares, 2021
Figure 166 Novartis AG: Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 167 Novartis AG: Regional Revenue Shares, 2021
Figure 168 Novartis AG: Segmental Revenue Shares, 2021
Figure 169 F. Hoffmann-La Roche Ltd : Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 170 F. Hoffmann-La Roche Ltd : Regional Revenue Shares, 2021
Figure 171 F. Hoffmann-La Roche Ltd : Segmental Revenue Shares, 2021
Figure 172 AstraZeneca: Net Revenue, 2017-2021 (US $ million, AGR %)
Figure 173 AstraZeneca: Regional Revenue Shares, 2021
Figure 174 Bristol-Myers Squibb Company: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 175 Bristol-Myers Squibb Company: Regional Revenue Shares, 2021
Figure 176 AbbVie Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 177 AbbVie Inc.: Product Revenue Shares, 2021
Figure 178 AbbVie Inc.: Regional Revenue Shares, 2021
Figure 179 Gilead Sciences, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 180 Gilead Sciences, Inc.: Product Revenue Shares, 2021
Figure 181 Gilead Sciences, Inc.: Regional Revenue Shares, 2021
Figure 182 Boehringer Ingelheim International GmbH : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 183 Boehringer Ingelheim International GmbH Product Revenue Shares, 2021
Figure 184 Boehringer Ingelheim International GmbH: Regional Revenue Shares, 2021
Figure 185 Cipla: Product Revenue Shares, 2021
Figure 186 Abbott: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 187 Abbott: Product Revenue Shares, 2021
Figure 188 Abbott: Regional Revenue Shares, 2021
Figure 189 Viatris: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 190 Viatris: Regional Revenue Shares, 2021
Figure 191 Sun Pharmaceutical Industries Ltd. : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 192 Sun Pharmaceutical Industries Ltd.: Regional Revenue Shares, 2021
Figure 193 Aurobindo Pharma: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 194 Dr. Reddy’s Laboratories Ltd. : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 195 Dr. Reddy’s Laboratories Ltd. : Product Revenue Shares, 2021
Figure 196 Antiviral Drugs Market Share Forecast by Region, 2022, 2026, 2032 (%)

この商品のレポートナンバー

0000033636

TOP